Chengdu Pukangweixin Biotechnology CO., LTD.

Chengdu Pukang Biotechnology Co., Ltd., established in 2008, is a high-tech enterprise specializing in the R&D and production of liquid-phase short peptides and deeply involved in long-acting peptide drug technology. Leveraging its long-term R&D accumulation and industrialization practice in the field of long-acting peptide side-chain technology, Chengdu Pukang was the sole drafting unit deeply involved in the formulation of the "Industry Guidelines for Pharmaceutical Research Technology of Long-Acting Fatty Acid Side Chains," completed the DMF registration of semaglutide and telpolide side chains, and provided CMC documents supporting more than 40 companies worldwide in completing drug registration and DMEF applications for active pharmaceutical ingredients. Currently, the company's products cover upstream raw materials for drugs such as GLP-1, oral cyclic peptides, and ADCs, meeting the supply needs from gram-level to flavor-level products. Pukang's four core technology platforms—a long-acting peptide side-chain platform, a short peptide platform, a non-natural amino acid platform, and a PEG derivative platform—provide integrated solutions for customers. Based on the long-acting side-chain platform, it offers a rich library of long-acting peptide building blocks, accelerating high-throughput screening and discovery of innovative drugs. Based on the short peptide platform, it provides high-purity short peptides, helping customers optimize processes, significantly improve crude peptide purity, shorten synthesis cycles, and reduce waste emissions. Pukang's industrialization advantages include: reactor sizes ranging from 100L to 5000L; reaction temperatures from -80℃ to 200℃; annual production capacity of 500 tons, including 100 tons of side-chain capacity; and a comprehensive quality system and EHS management system.